Sorin-Cyberonics Merger Receives U.S. Antitrust Approval

MILAN & HOUSTON--(BUSINESS WIRE)--Sorin S.p.A. (MIL:SRN) (MTA; Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc. (NASDAQ:CYBX), a medical device company with core expertise in neuromodulation, today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to their pending merger, has expired, thereby satisfying one of the conditions required to finalize the merger transaction.